Health Trials

Asciminib RMP Study

ConditionChronic Myeloid Leukemia
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-100
SponsorNovartis Pharmaceuticals

About this trial

This study is a prospective, open-label, multi-center, non-comparative, observational study to assess safety and effectiveness of Asciminib in the real-world clinical setting in Korean Chronic myeloid leukemia (CML) patients.

Eligibility criteria

Qualifiers

Adult patients diagnosed with Ph+ CP-CML and currently receiving or going to receive Scemblix® treatment according to locally approval label

Patients who are willing to provide written informed consent prior to study enrollment

Disqualifiers

Patients with contraindication according to locally approved label of Scemblix®

Patients who receive or are going to receive any investigational medicine during the observation period

Trial design

Treatments tested in this trial

  • Asciminib

Treatment groups

600 Participants
are divided into 1 treatment group

Locations

17
Novartis Investigative Site26426, WŏnjuGangwon-do, South Korea
Novartis Investigative Site14068, Anyang-siGyeonggi-do, South Korea
Novartis Investigative Site14584, Bucheon-siGyeonggi-do, South Korea
Novartis Investigative Site11759, Uijeongbu-siGyeonggi-do, South Korea

Sponsors and collaborators

Novartis Pharmaceuticals

Lead sponsor

Source ClinicalTrials.gov